Home›Research›Compare›Ac-SDKP vs TB-500
Peptide ComparisonAc-SDKP vs TB-500
Both are Tissue Repair peptides.
Ac-SDKP
N-acetyl-seryl-aspartyl-lysyl-proline
No providers listed yet
TB-500
thymosin beta 4
Half-life: 5–7 days
402 providers listed
Ac-SDKP carries stronger published evidence (Cohort study, 4 key studies) than TB-500 (Review, 3); both are research compounds.
Ac-SDKP
Evidence
Half-life
—
TB-500
Evidence
Half-life
5–7 days
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Ac-SDKP |
| More provider options (0 vs 402) | TB-500 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Ac-SDKP
TB-500
Ac-SDKP
Device surface-functionalized ac-SDKP nanoassemblies accelerate endothelial recovery through dual anti-inflam…
Ac-SDKP Attenuates Silica-Induced Pulmonary Fibrosis by Inhibiting ALKBH1-Mediated m(6)A Demethylation of miR…
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythe…
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis
TB-500
Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?
Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis
Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db…
About Ac-SDKP
Inhibits hematopoietic stem cell entry into S-phase. Blocks TGF-β1-mediated fibroblast activation, reducing collagen deposition. Promotes angiogenesis via VEGF upregulation. Regulated in vivo by ACE enzyme.
About TB-500
TB-500 exerts its effects primarily through promotion of actin polymerisation and cell migration. It upregulates the expression of beta-4 thymosin, which facilitates endothelial and muscle satellite cell movement to injury sites. Unlike BPC-157, TB-500 appears to act via a more systemic mechanism rather than locally at the administration site.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Ac-SDKP
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
TB-500
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
global — WADA
TB-500 / thymosin β4 is on the WADA Prohibited List at all times (S2.3, Growth Factors), effective 2018. It has no FDA approval and no human RCT evidence for injectable use.
sourceTB-500
BPC-157
Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.
Ac-SDKP
Not enough vendor pricing yet.
TB-500
Where to source these peptides
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Tissue Repair Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Ac-SDKP vs TB-500 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/ac-sdkp/tb-500